# Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer

> **NCT02768415** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 40 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Apatinib
- **DRUG:** Oral Vinorelbine

## Key facts

- **NCT ID:** NCT02768415
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2018-01
- **Final completion:** —
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2019-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02768415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02768415, "Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02768415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*